Research Calls
-
Upgrades:
- Amgen (AMGN) upgraded to Buy from Neutral at Daiwa Securities; tgt raised to $320
- Annexon (ANNX) upgraded to Buy from Neutral at BofA Securities; tgt raised to $6
- Extra Space Storage (EXR) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $150
- Glaukos (GKOS) upgraded to Overweight from Neutral at JP Morgan; tgt raised to $91
- Insulet (PODD) upgraded to Outperform from Neutral at Robert W. Baird; tgt raised to $238
- JFrog (FROG) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $42
- Merit Medical (MMSI) upgraded to Buy from Hold at Canaccord Genuity; tgt $100
- Regency Centers (REG) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $75
- Salesforce (CRM) upgraded to Overweight from Equal-Weight at Morgan Stanley; tgt raised to $350
- Spotify (SPOT) upgraded to Buy from Hold at Pivotal Research Group; tgt raised to $265
- Urban Edge Properties (UE) upgraded to Equal-Weight from Underweight at Morgan Stanley; tgt raised to $18
-
Downgrades:
- Eli Lilly (LLY) downgraded to Outperform from Buy at Daiwa Securities; tgt lowered to $610
- Highwoods Prop (HIW) downgraded to Underweight from Equal-Weight at Morgan Stanley; tgt lowered to $18
- Nevro (NVRO) downgraded to Hold from Buy at Canaccord Genuity; tgt $23
- POINT Biopharma (PNT) downgraded to Hold from Buy at Brookline
- Simon Properties (SPG) downgraded to Equal-Weight from Overweight at Morgan Stanley; tgt raised to $143
-
Others:
- Catalyst Pharma (CPRX) initiated with an Outperform at Oppenheimer; tgt $30
- Crinetics Pharmaceuticals (CRNX) initiated with a Hold at Jefferies; tgt $35
- J. Jill (JILL) initiated with an Outperform at William Blair
- Myriad Genetics (MYGN) resumed with a Neutral at Piper Sandler; tgt $23
- Ovid Therapeutics (OVID) initiated with a Buy at BTIG Research; tgt $11
- Rollins (ROL) initiated with an Equal-Weight at Morgan Stanley; tgt $42